Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
1
SHPH Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
-31.73%
Day range:
$0.89 - $0.93
52-week range:
$0.89 - $15.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.01x
Volume:
43.5K
Avg. volume:
4.7M
1-year change:
-93.53%
Market cap:
$9.8M
Revenue:
--
EPS (TTM):
-$14.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.70 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 3.55% | 5.27% | $89.48 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
$0.89 | -- | $9.8M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.50 | $31.70 | $3.8B | 9.83x | $0.00 | 0% | 3.56x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.65 | $457.00 | $42.3B | 141.18x | $0.00 | 0% | 11.45x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$58.53 | $89.48 | $11.3B | 32.85x | $0.00 | 0% | 3.51x |
|
IMNN
Imunon, Inc.
|
$3.26 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.58 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
32.37% | 2.058 | 1.71% | 1.07x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.788 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.412 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-$1K | -$2.3M | -449.76% | -697.07% | -- | -$2.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Shuttle Pharmaceuticals Holdings, Inc. vs. Competitors
-
Which has Higher Returns SHPH or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of 96.33%. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SHPHShuttle Pharmaceuticals Holdings, Inc.-- -$1.05 $2.1M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SHPH or ACAD?
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.70 which suggests that it could grow by 40.89%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SHPHShuttle Pharmaceuticals Holdings, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is SHPH or ACAD More Risky?
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock SHPH or ACAD?
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHPH or ACAD?
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 3.56x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHPHShuttle Pharmaceuticals Holdings, Inc.-- -- -- -$2.3M ACADACADIA Pharmaceuticals, Inc.3.56x 9.83x $284M $273.6M
-
Which has Higher Returns SHPH or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of 16.99%. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SHPHShuttle Pharmaceuticals Holdings, Inc.-- -$1.05 $2.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SHPH or ALNY?
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 43.42%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SHPHShuttle Pharmaceuticals Holdings, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is SHPH or ALNY More Risky?
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock SHPH or ALNY?
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHPH or ALNY?
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 11.45x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHPHShuttle Pharmaceuticals Holdings, Inc.-- -- -- -$2.3M ALNYAlnylam Pharmaceuticals, Inc.11.45x 141.18x $1.1B $186.4M
-
Which has Higher Returns SHPH or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of -5.2%. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital SHPHShuttle Pharmaceuticals Holdings, Inc.-- -$1.05 $2.1M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About SHPH or BMRN?
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.48 which suggests that it could grow by 52.88%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SHPHShuttle Pharmaceuticals Holdings, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is SHPH or BMRN More Risky?
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.
-
Which is a Better Dividend Stock SHPH or BMRN?
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHPH or BMRN?
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 32.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 3.51x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHPHShuttle Pharmaceuticals Holdings, Inc.-- -- -- -$2.3M BMRNBioMarin Pharmaceutical, Inc.3.51x 32.85x $895M -$46.6M
-
Which has Higher Returns SHPH or IMNN?
Imunon, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of --. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital SHPHShuttle Pharmaceuticals Holdings, Inc.-- -$1.05 $2.1M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About SHPH or IMNN?
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 559.51%. Given that Imunon, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Imunon, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SHPHShuttle Pharmaceuticals Holdings, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is SHPH or IMNN More Risky?
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.057, suggesting its more volatile than the S&P 500 by 105.729%.
-
Which is a Better Dividend Stock SHPH or IMNN?
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHPH or IMNN?
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than Imunon, Inc.'s net income of -$3.4M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHPHShuttle Pharmaceuticals Holdings, Inc.-- -- -- -$2.3M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns SHPH or SVRA?
Savara, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of --. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SHPHShuttle Pharmaceuticals Holdings, Inc.-- -$1.05 $2.1M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SHPH or SVRA?
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.77%. Given that Savara, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Savara, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SHPHShuttle Pharmaceuticals Holdings, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is SHPH or SVRA More Risky?
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock SHPH or SVRA?
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHPH or SVRA?
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHPHShuttle Pharmaceuticals Holdings, Inc.-- -- -- -$2.3M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
